Newly established ELISA for N-ERC/mesothelin improves diagnostic accuracy in patients with suspected pleural mesothelioma

Tadashi Sato¹, Yohei Suzuki¹, Takanori Mori¹, Masahiro Maeda², Masaaki Abe³, Okio Hino³ & Kazuhisa Takahashi¹

¹Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan
²Immuno-Biological Laboratories Co., Ltd., 1091-1 Naka, Fujioka, Gunma 375-0005, Japan
³Department of Pathology and Oncology, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan

Keywords
Area under the curve, biomarker, ELISA, N-ERC/mesothelin, pleural mesothelioma

Correspondence
Tadashi Sato, Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.
Tel: 81-3-5802-1063; Fax: 81-3-5802-1617; E-mail: satotada@juntendo.ac.jp

Abstract
Pleural mesothelioma is an aggressive tumor, commonly caused by exposure to asbestos. The prognosis of mesothelioma remains disappointing despite multimodal treatment. We reported previously that N-ERC/mesothelin could be a useful biomarker for the early diagnosis of pleural mesothelioma and developed an enzyme-linked immunosorbent assay (ELISA) system for its detection. However, the reproducibility of our previous 7–16 ELISA system has been revealed to be unsatisfactory. To measure N-ERC/mesothelin more precisely, we developed a new 7–20 ELISA system. The subjects of this study were patients who were referred to our department with suspected pleural mesothelioma. The current study demonstrated that the newly established 7–20 ELISA system improved the sensitivity and specificity for diagnosing pleural mesothelioma compared with the previous system. Moreover, the 7–20 ELISA system showed better reproducibility and displayed the tendency of both higher sensitivity and higher specificity in plasma than in serum. Particularly for the epithelioid type, the area under the curve (AUC) and the diagnostic accuracy of N-ERC/mesothelin were excellent; the AUC was 0.91, the sensitivity was 0.95, and the specificity was 0.76 in plasma. In conclusion, assessment of N-ERC/mesothelin with our newly established 7–20 ELISA system is clinically useful for the precise diagnosis of pleural mesothelioma.

Introduction
Mesothelioma is an aggressive malignant tumor, which initially progresses along the surfaces of the pleura and peritoneum and is most commonly caused by exposure to asbestos. Mesothelioma used to be considered extremely rare; however, the incidence of this disease is increasing worldwide due to widespread asbestos exposure. Pleural mesothelioma, the most common form of mesothelioma, is characterized by pleural thickening on chest radiography and pleural effusions in many cases. Some reports have described the effectiveness of combination chemotherapy with pemetrexed plus cisplatin and multimodal treatment [1–4]. However, the prognosis of mesothelioma remains disappointing. Early diagnosis of mesothelioma is essential to improve prognosis. The development of biomarkers is considered crucial for the early diagnosis of mesothelioma. To date, several biomarkers have been reported to be useful in diagnosing mesothelioma, including cytokeratin 19 fragment [5], tissue polypeptide antigen [5, 6], hyaluronan [6, 7], carbohydrate antigen 125 [6, 8], osteopontin [9, 10], and soluble mesothelin-related protein (SMRP) [11–14]. However, the sensitivity and specificity of these markers are thought to be unsatisfactory.
We previously discovered the renal carcinoma gene *ERC*, which is highly expressed in renal carcinomas in the Eker rat [15]. We subsequently revealed that *ERC* is a homolog of the human mesothelin gene, which is the causative gene for mesothelioma [16, 17]. The human mesothelin gene product is cleaved by a furin-like protease to form a 31-kDa N-terminal fragment (N-ERC/mesothelin) that is physiologically secreted into the blood [18]. We further demonstrated that N-ERC/mesothelin could be a useful biomarker for the early diagnosis of pleural mesothelioma and established an enzyme-linked immunosorbent assay (ELISA) using mAb clone 7E7 and clone 16K16 (7–16 ELISA) for the detection of N-ERC/mesothelin with relatively high sensitivity and specificity [19, 20]. However, the reproducibility of the 7–16 ELISA system has been revealed to be unsatisfactory. Therefore, the current study was designed to improve the 7–16 ELISA system using a novel mAb clone and to demonstrate the clinical usefulness of the modified ELISA system in patients with suspected pleural mesothelioma.

**Materials and Methods**

**Preparation of novel anti-ERC/mesothelin antibodies**

The anti-N-ERC/mesothelin mAb clone 7E7 has been described previously [19, 20]. In order to improve the previous ELISA system, we established a novel mAb clone, 20A2, following the same procedure.

**Epitope mapping of mAbs against N-ERC/mesothelin**

The epitope of mAb 20A2 was searched against a series of deletion mutants of recombinant N-ERC/mesothelin protein expressed in an in vitro translation system using wheat germ extract, as described previously [19, 20].

A series of recombinant proteins produced using the deletion mutant N-ERC/mesothelin construct was analyzed using western blotting analysis with mAb 20A2 to identify epitopes as described [19].

**Novel sandwich ELISA using mAb 20A2**

A novel sandwich ELISA system using clone 20A2 was established in a manner described previously [19, 20].

**ELISA validation**

In order to assess the intra- and interassay precision of the ELISAs, three quality controls (QCs) were established covering the high, middle, and low range of the standard curves. Intra-assay precision was determined by four repeated measurements of each QC sample in a plate, and interassay precision was established by assessing each QC sample across three different plates with quadruple wells. The sensitivity of this novel ELISA system was determined based on the guidelines provided by the National Committee for Clinical Laboratory Standards (NCCLS) Evaluation Protocols.

**Detection and quantification of N-ERC/mesothelin in blood samples**

The concentrations of N-ERC/mesothelin in both plasma and sera from patients with pleural mesothelioma and study subjects with other related conditions were measured after eightfold dilution in 1% bovine serum albumin in phosphate-buffered saline with 0.1% Tween 20.

**Patients**

The subjects of this study were patients who were referred to the Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Japan, and suspected to have pleural mesothelioma mainly on the basis of the existence of pleural effusion, pleural thickening, and a history of exposure to asbestos. Patients were prospectively enrolled from June 2005 to March 2013. The study was approved by the Institutional Review Board of Juntendo University Graduate School of Medicine, Japan. All patients provided signed informed consent. Blood sampling to determine the level of N-ERC/mesothelin was conducted in daily clinical practice, prior to and independent of the final diagnosis. Whole blood was collected in a covered test tube, after which serum was prepared by allowing it to clot at room temperature for 30 min. The clot was removed by centrifuging at 2000 g for 10 min in a refrigerated centrifuge. The resulting supernatant was designated serum and transferred into a clean polypropylene tube, aliquoted and stored at −20°C or lower. For plasma preparation, whole blood was collected in an EDTA-treated tube. Cells were removed by centrifugation for 10 min at 2000 g using a refrigerated centrifuge. The resulting supernatant was designated plasma and stored as described above for serum samples. The measurements of N-ERC/mesothelin were performed by one specialist in a blinded fashion at the Department of Pathology and Oncology, Juntendo University Graduate School of Medicine, Japan. Tissue sections were obtained from archived paraffin-embedded tumor blocks from thoracoscopic biopsies or surgeries. Mesothelioma was diagnosed with immunohistochemistry as described previously [20]. Other diseases were diagnosed comprehensively, using both pathologic and clinical information.
**Statistical analysis**

Values were analyzed using the GraphPad Prism 5 (GraphPad Software, Inc., San Diego, CA). Analysis of variance (ANOVA) was performed using the nonparametric Kruskal–Wallis test. A $P < 0.05$ was considered significant. The area under the curve (AUC) of the receiving operating characteristics (ROC) curve was calculated using the trapezoidal method (StatFlex, Artech Co., Ltd., Osaka, Japan). To examine the cut-off values, we first calculated the total value of the specificity and sensitivity for each cut-off value and then chose the best cut-off values.

**Results**

**Establishment of a novel 7–20 ELISA system**

In order to measure the N-ERC/mesothelin concentration more precisely, we developed a novel sandwich N-ERC/mesothelin ELISA system, which is a combination of mAbs 7E7 and 20A2 (7–20 ELISA system). The epitope of mAb 20A2 was located in the 98–109 amino acid region of N-ERC/mesothelin (Fig. 1A). The molecular weight of GST is 25 kDa, and the molecular weight of the Histagged ERC (hERC) proteins 1–295, 1–121, 1–109, and 1–97 are ~29.5, 12.1, 10.9, and 9.7 kDa, respectively. Thus, as fusion proteins, the molecular weight of GST-hERC 1–295, GST-hERC 1–121, GST-hERC 1–109, and GST-hERC 1–97 are ~54.5, 37.1, 35.9, and 34.7 kDa, respectively (Fig. 1B). The mAb 20A2 detected hERC 1–121 and 1–109, but not 1–97. In the novel 7–20 ELISA system, mAb 7E7 was used as the capture antibody and 20A2 was used as the detection antibody (Fig. 1C).

The standard dose–response curve for the N-ERC/mesothelin ELISA system exhibited a linear shape when plotted on a log/log scale over a range from 0.07 to 4.4 ng/mL and the linearity was excellent ($R^2 = 0.99$) (Fig. 2). The precision was determined with three spiked QC samples (high [H], middle [M], and low [L]). The intra-assay precision, determined by four repeated measurements of each QC sample in a plate, exhibited a coefficient of variation (CV) of 0.8% in H, 0.5% in M, and 1.7% in L (Table 1, intra-assay). Additionally, the interassay precision, determined by assessing each QC sample across three different plates, indicated a CV of 9.6% in H, 15.1% in M, and 7.0% in L (Table 1, interassay). Thus, the novel ELISA system can be considered fully reliable from the standpoint of precision. The assay sensitivity was calculated to be 24 pg/mL using NCCLS methods. In contrast, for the previous 7–16 ELISA system, the intra-assay precision exhibited a CV of 18.7% in H, 22.0% in M, and 12.3% in L (Table 1, interassay). These findings supported the superiority of the novel 7–20 ELISA system compared to the 7–16 ELISA system.

**Comparison of the novel 7–20 ELISA system with the previous 7–16 ELISA system in blood samples from patients with suspected pleural mesothelioma**

We recruited a total of 53 patients. Among them, 28 patients had confirmed mesothelioma, of which 21 cases were epithelioid, five were sarcomatoid, and two were biphasic type according to the pathological findings. In contrast, 25 patients were diagnosed with other conditions, as shown in Table 2.

The two ELISA systems showed a good correlation in the measurement of blood samples ($R^2 = 0.959$ in sera, $R^2 = 0.975$ in plasma), which suggested that data...
obtained with the novel 7–20 ELISA system could be compared to previous data obtained using the earlier 7–16 ELISA system (Fig. 3).

We next evaluated the differences in N-ERC/mesothelin levels among each histologic type of pleural mesothelioma using the 7–20 ELISA system, because we have previously reported, using our former 7–16 ELISA system, that the epithelioid type shows higher levels of N-ERC/mesothelin in sera compared with other histologic types [20]. In the current study, both sera and plasma N-ERC/mesothelin levels of the epithelioid type were significantly higher than the values of the sarcomatoid and biphasic types, as well as those of nonmesothelioma conditions (Fig. 4A and B).

We further conducted ROC analysis comparing the 7–20 ELISA system with the 7–16 ELISA system (Fig. 5A and B). On comparing all mesothelioma patients with

Table 1. Validation of ELISA systems by intra- and interassay.

|                  | Values (ng/mL) | SD  | %CV |
|------------------|----------------|-----|-----|
| **Intra-assay**  |                |     |     |
| 7–20 ELISA system| High           | 1.678| 0.014| 0.8 |
|                  | Middle         | 0.427| 0.002| 0.5 |
|                  | Low            | 0.158| 0.003| 1.7 |
| 7–16 ELISA system| High           | 1.110| 0.210| 18.5|
|                  | Middle         | 0.260| 0.010| 2.4 |
|                  | Low            | 0.100| 0.010| 5.9 |
| **Interassay**   |                |     |     |
| 7–20 ELISA system| High           | 1.521| 0.145| 9.6 |
|                  | Middle         | 0.366| 0.055| 15.1|
|                  | Low            | 0.149| 0.010| 7.0 |
| 7–16 ELISA system| High           | 1.025| 0.191| 18.7|
|                  | Middle         | 0.289| 0.063| 22.0|
|                  | Low            | 0.108| 0.013| 12.3|

The intra-assay results were derived from analyses in quadruplicate for each quality control (QC). The interassay results were based on three separate measurements of each QC in quadruplicate. CV, coefficient of variation; ELISA, enzyme-linked immunosorbent assay.

The values of the sarcomatoid and biphasic types, as well as those of nonmesothelioma conditions (Fig. 4A and B). We further conducted ROC analysis comparing the 7–20 ELISA system with the 7–16 ELISA system (Fig. 5A and B). On comparing all mesothelioma patients with
nonmesothelioma patients, the AUCs were 0.77 in sera and 0.82 in plasma by 7–20 ELISA and 0.74 in sera and 0.74 in plasma by 7–16 ELISA (Fig. 5A). On comparing only patients with the epithelioid type with nonmesothelioma patients, the AUCs were 0.89 in sera and 0.91 in plasma by 7–20 ELISA and 0.85 in sera and 0.86 in plasma by 7–16 ELISA (Fig. 5B). In both ELISA systems, plasma samples showed higher AUCs than sera samples.

In addition, we compared the statistical best sensitivity and specificity. In the case of all mesothelioma patients versus other patients, the best sensitivity and specificity were 0.68 and 0.68 (cut-off value: 6.66 ng/mL) in sera and 0.79 and 0.76 (4.98 ng/mL) in plasma by 7–20 ELISA (Fig. 5A). On comparing only patients with the epithelioid type with nonmesothelioma patients, the AUCs were 0.89 in sera and 0.91 in plasma by 7–20 ELISA and 0.85 in sera and 0.86 in plasma by 7–16 ELISA (Fig. 5B). In both ELISA systems, plasma samples showed higher AUCs than sera samples.

Figure 4. Scatter plots of N-ERC/mesothelin values of epithelioid type (Epi, n = 21), sarcomatoid and biphasic type (Sar + Bip, n = 7), and nonmesothelioma patients (Non, n = 25) measured by the 7–20 ELISA system. Values in (A) sera and (B) plasma. *P < 0.01 and **P < 0.001.

Figure 5. Receiving operating characteristics curve analysis comparing the 7–20 ELISA system with the 7–16 ELISA system using both sera and plasma samples. (A) Comparison of all pleural mesothelioma patients (Meso, n = 28) with nonmesothelioma patients (Non, n = 25). (B) Comparison of epithelioid type patients (Epi, n = 21) with nonmesothelioma patients (Non, n = 25).

and specificity were 0.81 and 0.80 (cut-off value: 9.16 ng/mL) in sera and 0.95 and 0.76 (4.97 ng/mL) in plasma by 7–20 ELISA compared to 0.76 and 0.76 (9.46 ng/mL) in
sera and 0.81 and 0.76 (7.62 ng/mL) in plasma by 7–16 ELISA (Fig. 5B). As these results show, the AUC and the diagnostic accuracy of pleural mesothelioma with the novel 7–20 ELISA system were higher than those with the former system both in sera and plasma samples.

Discussion

The present study demonstrates that a newly established ELISA system for N-ERC/mesothelin, the 7–20 ELISA system, improved the AUCs, sensitivity, and specificity for the diagnosis of pleural mesothelioma in the current cohort compared with our previous system. Moreover, the 7–20 ELISA system showed better reproducibility by both the intra- and interassay measurements. We have previously reported that the AUCs, sensitivity, and specificity of the 7–16 ELISA system were about 0.85–0.93, 0.71–0.90, and 0.88–0.93, respectively [20]. The values for the AUCs and the sensitivity in the current study are excellent, particularly for the epithelioid type of pleural mesothelioma. In contrast, the values for the specificity seem to decrease slightly compared with those in the previous report because the sample size of this study is smaller and the subject characteristics are considered different.

The current study assessed patients referred to our department with suspected pleural mesothelioma based on a review of the patient’s medical history and findings of imaging studies. Diagnosis in the early stages of pleural mesothelioma, in particular, is often very difficult, because the symptoms are similar to those of a number of other conditions. Therefore, we believe that a blood biomarker is an ideal tool for the early diagnosis of mesothelioma, and the current 7–20 ELISA system for N-ERC/mesothelin is clinically useful as an excellent biomarker for pleural mesothelioma.

To date, SMRP has been the most extensively studied biomarker in blood. SMRP is a 40-kDa cell surface glycoprotein that is a soluble form of mesothelin. SMRP can also be detected by sandwich ELISA containing two mAbs (OV569 and 4H3), which bind to the C-terminal fragment [11]. This assay was commercialized as Mesomark™ (Fujirebio Diagnostics, Inc., Malvern, PA) and was approved in 2007 by the US Food and Drug Administration to aid in the monitoring of patients with epithelioid and biphasic mesothelioma [21]. However, a recent meta-analysis demonstrated that SMRP is limited by an overall sensitivity of 0.47 at 0.96 specificity [22]. Moreover, a more recent study showed that N-ERC/mesothelin as measured by our previous 7–16 ELISA was a better predictor of mesothelioma than C-ERC/mesothelin as assessed by Mesomark™ judging from odds ratios and ROC curves [23]. Fibulin-3 is a highly conserved member of the extracellular glycoprotein fibulin family. Pass et al. have recently reported that plasma fibulin-3 levels can distinguish healthy individuals with exposure to asbestos from pleural mesothelioma patients with both high sensitivity and high specificity [24]. Although neither SMRP nor fibulin-3 were evaluated using the same samples in the current study, we should consider comparing them to N-ERC/mesothelin levels assessed by the novel 7–20 ELISA system as a next step.

The current study demonstrated that our ELISA system for N-ERC/mesothelin tended to have higher AUCs, sensitivity, and specificity in plasma than in serum. We also observed that it showed better reproducibility for plasma N-ERC/mesothelin levels than for serum levels (data not shown). Although we have not determined the mechanism of those differences between plasma and serum, at present, we recommend assessing N-ERC/mesothelin with our ELISA system in plasma rather than in serum. In addition, we do not have enough data from assessments of pleural effusions with our ELISA system. SMRP has been reported to be more useful in pleural effusions than in serum in the diagnosis of pleural mesothelioma [25]. In contrast, effusion fibulin-3 levels were found to be significantly higher in patients with pleural mesothelioma than in those with effusions not due to mesothelioma; however, they did not correlate with plasma levels [24]. The diagnostic accuracy of N-ERC/mesothelin in pleural effusion will need to be explored in further studies.

The current study also demonstrates that the diagnostic accuracy of N-ERC/mesothelin is significantly higher for the epithelioid type than for other histologic types of pleural mesothelioma. We have already reported that serum levels of N-ERC/mesothelin, which were assessed with the 7–16 ELISA system, were particularly elevated in the epithelioid type [20]. As for treatment strategies for pleural mesothelioma, the epithelioid type is the most important at present because of its sensitivity to the currently available therapies. We therefore believe N-ERC/mesothelin is a useful biomarker in the clinical course of pleural mesothelioma from this aspect.

The current study is limited by the small number of patients, although they were prospectively recruited throughout the period of this study. Therefore, there may be no significant difference in any of the comparative measures between the 7–20 and 7–16 ELISA systems in the current study. Since pleural mesothelioma is a rare disease, it is difficult to recruit sufficient patients from a single department. Therefore, a multicenter clinical trial is needed to fully evaluate the diagnostic potential of N-ERC/mesothelin for pleural mesothelioma.

In conclusion, to assess N-ERC/mesothelin with our newly established ELISA system is clinically useful because of the system’s technological improvement. We have previously reported that N-ERC/mesothelin is useful not only
for diagnosis but also for monitoring chemotherapeutic response and for predicting prognosis in patients with pleural mesothelioma [26–28]. Mundt et al. have recently reported that a two-step model using hyaluronan and N-ERC/mesothelin predicts pleural mesothelioma with high specificity [23]. As a next step, we should assess the combination of N-ERC/mesothelin with other biomarkers for pleural mesothelioma, by means of which patients suffering from this disease might obtain benefits throughout their clinical course.

Acknowledgments

The authors thank Naoko Aoki for assistance in the management of this study. This study was supported in part by a Grant-in-Aid for Cancer Research from the Ministry of Education, Culture, Sports, Science (O. H., 22240093).

Conflict of Interest

None declared.

References

1. Sugarbaker, D. J., R. M. Flores, M. T. Jaklitsch, W. G. Richards, G. M. Strauss, J. M. Corson, et al. 1999. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J. Thor. Cardiovas. Surg. 117:54–63; discussion 63–5.
2. Vogelzang, N. J., J. J. Rusthoven, J. Symanowski, C. Denham, E. Kaukel, P. Ruffie, et al. 2003. Phase III study of pemtrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 21:2636–2644.
3. Krug, L. M., H. I. Pass, V. W. Rusch, H. L. Kindler, D. J. Sugarbaker, K. E. Rosenzweig, et al. 2009. Multicenter phase II trial of neoadjuvant pemtrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J. Clin. Oncol. 27:3007–3013.
4. Van Schil, P. E., P. Baas, R. Gafar, A. P. Maat, M. Van de Pol, B. Hasan, et al. 2010. European Organisation for R, Treatment of Cancer Lung Cancer G. Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial. The. Eur. Respir. J. 36:1362–1369.
5. Bonfrer, J. M., J. H. Schouwink, C. M. Korse, and P. Baas. 1997. Cyfra 21-1 and TPA as markers in malignant mesothelioma. Anticancer Res. 17:2971–2973.
6. Hedman, M., H. Arnberg, J. Wernlund, H. Riska, and O. Brodin. 2003. Tissue polypeptide antigen (TPA), hyaluronan and CA 125 as serum markers in malignant mesothelioma. Anticancer Res. 23:531–536.
7. Welker, L., M. Muller, O. Holz, E. Vollmer, H. Magnussen, and R. A. Jorres. 2007. Cytological diagnosis of malignant mesothelioma—improvement by additional analysis of hyaluronic acid in pleural effusions. Virchows Arch. 450:455–461.
8. Creaney, J., I. van Bruggen, M. Hof, A. Segal, A. W. Musk, N. de Klerk, et al. 2007. Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma. Chest 132:1239–1246.
9. Pass, H. I., D. Lott, F. Lonardo, M. Harbut, Z. Liu, N. Tang, et al. 2005. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N. Engl. J. Med. 353:1564–1573.
10. Grigoriu, B. D., A. Scherpereel, P. Devos, B. Chahine, M. Letourneux, P. Lebailly, et al. 2007. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin. Cancer Res. 13:2928–2935.
11. Robinson, B. W., J. Creaney, R. Lake, A. Nowak, A. W. Musk, N. de Klerk, et al. 2003. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 362:1612–1616.
12. Robinson, B. W., J. Creaney, R. Lake, A. Nowak, A. W. Musk, N. de Klerk, et al. 2005. Soluble mesothelin-related protein—a blood test for mesothelioma. Lung cancer 49 (Suppl. 1):S109–S111.
13. Hassan, R., A. T. Remaley, M. L. Sampson, J. Zhang, D. D. Cox, J. Pingpangk, et al. 2006. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin. Cancer Res. 12:447–453.
14. Scherpereel, A., B. Grigoriu, M. Conti, T. Gey, M. Gregoire, M. C. Copin, et al. 2006. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am. J. Respir. Crit. Care Med. 173:1155–1160.
15. Hino, O., E. Kobayashi, M. Nishizawa, Y. Kubo, T. Kobayashi, Y. Hirayama, et al. 1995. Renal carcinogenesis in the Eker rat. J. Cancer Res. Clin. Oncol. 121:602–605.
16. Yamashita, Y., M. Yokoyama, E. Kobayashi, S. Takai, and O. Hino. 2000. Mapping and determination of the cDNA sequence of the Erc gene preferentially expressed in renal cell carcinoma in the Tsc2 gene mutant (Eker) rat model. Biochem. Biophys. Res. Commun. 275:134–140.
17. Hino, O. 2004. Mutistep renal carcinogenesis in the Eker (Tsc 2 gene mutant) rat model. Curr. Mol. Med. 4:807–811.
18. Hassan, R., T. Bera, and I. Pastan. 2004. Mesothelin: a new target for immunotherapy. Clin. Cancer Res. 10:3937–3942.
19. Shiomi, K., H. Miyamoto, T. Segawa, Y. Hagiwara, A. Ota, M. Maeda, et al. 2006. Novel ELISA system for detection of N-ERC/mesothelin in the sera of mesothelioma patients. Cancer Sci. 97:928–932.
20. Shiomi, K., Y. Hagiwara, K. Sonoue, T. Segawa, K. Miyashita, M. Maeda, et al. 2008. Sensitive and specific
new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma. Clin. Cancer Res. 14:1431–1437.
21. Li, Z. Q., T. Verch, and W. J. Allard. 2007. MESOMARK ((R)) in vitro diagnostic test for mesothelioma. Expert Opin. Med. Diagn. 1:137–142.
22. Hollevoet, K., J. B. Reitsma, J. Creaney, B. D. Grigoriu, B. W. Robinson, A. Scherpereel, et al. 2012. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J. Clin. Oncol. 30:1541–1549.
23. Mundt, F., G. Nilsonne, S. Arslan, K. Csuros, G. Hillerdal, H. Yıldırım, et al. 2013. Hyaluronan and N-ERC/mesothelin as key biomarkers in a specific two-step model to predict pleural malignant mesothelioma. PLoS One 8:e72030.
24. Pass, H. I., S. M. Levin, M. R. Harbut, J. Melamed, L. Chiriboga, J. Donington, et al. 2012. Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N. Engl. J. Med. 367:1417–1427.
25. Ferro, P., P. A. Canessa, E. Battolla, P. Dessanti, M. C. Franceschini, L. Chiaffò, et al. 2013. Mesothelin is more useful in pleural effusion than in serum in the diagnosis of pleural mesothelioma. Anticancer Res. 33:2707–2713.
26. Tajima, K., M. Hiramia, K. Shiomi, T. Ishiwata, M. Yoshioka, A. Iwase, et al. 2008. ERC/mesothelin as a marker for chemotherapeutic response in patients with mesothelioma. Anticancer Res. 28:3933–3936.
27. Imashimizu, K., K. Shiomi, M. Maeda, N. Aoki, K. Igarashi, F. Suzuki, et al. 2011. Feasibility of large-scale screening using N-ERC/mesothelin levels in the blood for the early diagnosis of malignant mesothelioma. Exp. Ther. Med. 2:409–411.
28. Mori, T., K. Tajima, M. Hiramia, T. Sato, K. Kido, S. Iwakami, et al. 2013. The N-ERC index is a novel monitoring and prognostic marker for advanced malignant pleural mesothelioma. J. Thorac. Dis. 5:145–148.